3 min read
Measuring What Can't Be Seen: How PTSD Clinical Trials Prove a Drug Works
When an oncology drug is tested, the signal is often brutally clear. A tumor either shrinks on a scan or it does not. A...
Meet Veristat at RAPS US Convergence 2025
Where Regulatory Excellence Meets Real-World Impact
Veristat is delighted to participate in RAPS US Convergence 2025, the leading regulatory affairs conference in North America. The event will be held October 7–9, 2025, at the David L. Lawrence Convention Center in Pittsburgh, PA.
This premier conference brings together global experts to explore the latest trends and challenges in healthcare regulation, with focused sessions on devices, IVDs, pharmaceuticals, AI, software, and more.
Visit Us at Booth #310
As a leading global clinical research organization (CRO) and consultancy, discover how Veristat blends deep scientific knowledge with strategic regulatory insight to guide sponsors through every stage of clinical development. Whether you're:
-
Building a regulatory strategy
-
Preparing for agency meetings
-
Advancing to pivotal Phase 3 trials
-
Planning a global marketing submission
With 190+ marketing applications and 180+ INDs/CTAs prepared in past 5 years, Veristat is at the forefront of regulatory excellence. Meet us at RAPS US Convergence 2025 to see how our experience and flexibility can help accelerate your path to approval.
Veristat Attendees
-
Alison Bawden - Senior Director, Regulatory Affairs
-
Victor Zevallos - Senior Business Development Director
-
Mandy McCormick - Business Development Manager
Conference Details
As a leading global clinical research organization (CRO) and consultancy, discover how Veristat blends deep scientific knowledge with strategic regulatory insight to guide sponsors through every stage of clinical development. Whether you're:
-
Event: RAPS US Convergence 2025
-
Dates: October 7-9, 2025
-
Booth number: 310
-
Location: David L. Lawrence Convention Center, Pittsburgh, Pennsylvania
Schedule a Meeting
Let’s connect! Meet with our regulatory experts to explore how Veristat can help you navigate global regulatory pathways and bring your therapies to market faster.
Schedule A Meeting
3 min read
The Psychedelic Setback: What MDMA Rejection Taught Drug Developers
Apr 24, 2026 Veristat Blog
In August 2024, the FDA declined to approve MDMA-assisted therapy for post-traumatic stress disorder. The decision...